ATE553118T1 - Modifiziertes clostridiumtoxin mit geänderter biologischer persistenz - Google Patents

Modifiziertes clostridiumtoxin mit geänderter biologischer persistenz

Info

Publication number
ATE553118T1
ATE553118T1 AT01996547T AT01996547T ATE553118T1 AT E553118 T1 ATE553118 T1 AT E553118T1 AT 01996547 T AT01996547 T AT 01996547T AT 01996547 T AT01996547 T AT 01996547T AT E553118 T1 ATE553118 T1 AT E553118T1
Authority
AT
Austria
Prior art keywords
altered biological
biological persistence
clostridium toxin
modified clostridium
modified
Prior art date
Application number
AT01996547T
Other languages
English (en)
Inventor
Lance Steward
Athena Spanoyannis
Wei-Jen Lin
Kei Aoki
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22943921&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE553118(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE553118T1 publication Critical patent/ATE553118T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT01996547T 2000-11-17 2001-11-16 Modifiziertes clostridiumtoxin mit geänderter biologischer persistenz ATE553118T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24954000P 2000-11-17 2000-11-17
PCT/US2001/044030 WO2002040506A2 (en) 2000-11-17 2001-11-16 Modified clostridial neurotoxins with altered biological persistence

Publications (1)

Publication Number Publication Date
ATE553118T1 true ATE553118T1 (de) 2012-04-15

Family

ID=22943921

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01996547T ATE553118T1 (de) 2000-11-17 2001-11-16 Modifiziertes clostridiumtoxin mit geänderter biologischer persistenz

Country Status (7)

Country Link
US (1) US20020127247A1 (de)
EP (1) EP1334120B1 (de)
JP (1) JP2004536778A (de)
AT (1) ATE553118T1 (de)
AU (2) AU1985002A (de)
CA (2) CA2428136A1 (de)
WO (1) WO2002040506A2 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903187B1 (en) 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
AU2003272800A1 (en) 2002-10-01 2004-04-23 University Of Maryland Methods for identifying inhibitors of botulinum neurotoxins
MXPA05003936A (es) * 2002-10-15 2005-06-17 Allergan Inc Terapias y procedimientos odontologicos con toxina botulinica.
WO2004076634A2 (en) * 2003-02-24 2004-09-10 Ira Sanders Cell membrane translocation of regulated snare inhibitors , compositions therefor, and methods for treatment of disease
HUE025656T2 (en) * 2004-03-03 2016-04-28 Revance Therapeutics Inc Topical application and transdermal delivery of botulinum toxins
BRPI0508440A (pt) 2004-03-03 2007-07-24 Revance Therapeutics Inc composições e métodos para diagnóstico tópico e transporte terapêutico
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US7514088B2 (en) 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
KR20070110402A (ko) 2005-03-03 2007-11-16 레반스 테라퓨틱스 보툴리눔 독소의 국소 적용 및 경피 전달을 위한 조성물 및방법
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
WO2007059528A2 (en) * 2005-11-17 2007-05-24 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
WO2008082889A2 (en) * 2006-12-29 2008-07-10 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from hiv-tat
NZ598159A (en) * 2006-12-29 2013-08-30 Revance Therapeutics Inc Transport molecules using reverse sequence hiv-tat polypeptides
DK2178549T3 (en) * 2007-07-26 2017-01-09 Revance Therapeutics Inc Antimicrobial peptide AND COMPOSITIONS THEREOF
AU2010267963B2 (en) * 2009-07-02 2015-09-24 Merz Pharma Gmbh & Co. Kgaa Neurotoxins exhibiting shortened biological activity
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
WO2014066916A2 (en) 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and methods for safe treatment of rhinitis
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
ES2749862T3 (es) 2014-01-27 2020-03-24 Molecular Templates Inc Polipéptidos efectores desinmunizados de subunidad A de toxina Shiga para aplicaciones en mamíferos
EP3113792B1 (de) 2014-03-05 2018-12-05 Merz Pharma GmbH & Co. KGaA Neuartige rekombinante clostridienneurotoxinen mit verlängerter wirkungsdauer
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
WO2016110662A1 (en) 2015-01-09 2016-07-14 Ipsen Bioinnovation Limited Cationic neurotoxins
WO2016180533A1 (en) * 2015-05-12 2016-11-17 Merz Pharma Gmbh & Co. Kgaa Novel recombinant clostridial neurotoxins with increased duration of effect
CN114656573B (zh) * 2015-05-30 2024-09-27 分子模板公司 去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子
TW201718627A (zh) 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
ES2929347T3 (es) 2016-01-20 2022-11-28 Merz Pharma Gmbh & Co Kgaa Nuevas neurotoxinas clostridiales recombinantes con aumento de la duración del efecto
MX395130B (es) 2016-03-02 2025-03-24 Merz Pharma Gmbh & Co Kgaa Composicion que comprende toxina botulinica
EP3290437A1 (de) 2016-08-31 2018-03-07 Merz Pharma GmbH & Co. KGaA Neuartige rekombinante clostridienneurotoxine mit verkürzter wirkungsdauer
EP3312193A1 (de) 2016-10-19 2018-04-25 Merz Pharma GmbH & Co. KGaA Neuartige rekombinante botulinumneurotoxine mit beschleunigter wirkung
MX2019006656A (es) 2016-12-07 2019-09-09 Molecular Templates Inc Polipeptidos efectores de la sub-unidad a de la toxina shiga andamiajes de los efectores de la toxina shiga y moleculas con direccion hacia las celulas para la conjugacion especifica del sitio.
KR102590672B1 (ko) 2017-01-25 2023-10-18 몰레큘러 템플레이츠, 인코퍼레이션. 탈면역된 시가 독소 a 서브유닛 이펙터 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
EP3642222A1 (de) 2017-06-20 2020-04-29 Merz Pharma GmbH & Co. KGaA Neuartiges rekombinantes botulinumtoxin mit erhöhter wirkdauer
US11155802B2 (en) 2017-07-06 2021-10-26 Merz Pharma Gmbh & Co. Kgaa Recombinant botulinum neurotoxins with increased duration of effect
WO2019081022A1 (en) 2017-10-26 2019-05-02 Merz Pharma Gmbh & Co. Kgaa NOVEL RECOMBINANT BOTULINUM NEUROTOXINS WITH INCREASED DURATION
BR112020006827A2 (pt) 2018-01-29 2020-10-06 Ipsen Biopharm Limited neurotoxinas botulínicas clivando snare não neuronal
JP6867452B2 (ja) * 2019-08-09 2021-04-28 イプセン バイオイノベーション リミテッド 陽イオン性神経毒
WO2023105289A1 (en) 2021-12-06 2023-06-15 Dublin City University Methods and compositions for the treatment of pain

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE215832T1 (de) 1994-05-09 2002-04-15 William J Binder Botulinumtoxin zur reduktion von migraine - kopfschmerzen
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
WO1996039166A1 (en) * 1995-06-06 1996-12-12 Wisconsin Alumni Research Foundation Analogs of botulinum toxin and pharmaceutical compositions of botulinum toxin
WO1997032599A1 (en) * 1996-03-08 1997-09-12 The Regents Of The University Of California Chemically-modified clostridiatoxin with improved properties
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
CA2422730A1 (en) * 2000-09-19 2002-03-28 Microbia, Inc. Modulation of secondary metabolite production by zinc binuclear cluster proteins

Also Published As

Publication number Publication date
EP1334120B1 (de) 2012-04-11
CA2632696A1 (en) 2002-05-23
EP1334120A2 (de) 2003-08-13
CA2428136A1 (en) 2002-05-23
AU1985002A (en) 2002-05-27
US20020127247A1 (en) 2002-09-12
WO2002040506A2 (en) 2002-05-23
JP2004536778A (ja) 2004-12-09
WO2002040506A3 (en) 2003-03-27
AU2002219850B2 (en) 2006-08-10

Similar Documents

Publication Publication Date Title
AU1985002A (en) Modified clostridial neurotoxins with altered biological persistence
MXPA03000576A (es) Motivo a base de leucina y neurotoxinas clostridial.
ATE382693T1 (de) Impfstoffe gegen neurotoxine von clostridium botulinum
DE69435307D1 (de) Bazillus Thuringiensis und dessen insektizide Proteine
ATE416191T1 (de) Abbaubare clostridientoxine
DE60142839D1 (de) Botulinum Toxin zur Behandlung von akuten Verletzungen der Skelettmuskeln
WO2002044199A3 (en) Neurotoxins with enhanced target specificity
ATE239491T1 (de) Verbesserte zusammensetzungen und verfahren zur chemodenervation mit neurotoxinen
TR200100728T2 (tr) Botulinum toksininin stabil sıvı formülasyonları
WO2006138059A3 (en) Treatment of autoimmune disorders with a neurotoxin
KR970064594A (ko) 노화방지용 화장품 조성물
WO2005030119A3 (en) Botulinum toxin a peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy
DK1796646T3 (da) Kosmetiske neurotoksinsammensætninger omfattende en botulinumtoksinbestanddel samt tilhörende fremgangsmåder
DE69333951D1 (de) Rekombinantes pseudomonas exotoxin mit gesteigerter aktivität
WO2001054711A3 (en) Use of neurotoxins for treating diabetes
ATE229313T1 (de) Kosmetische zusammensetzung, die ein anionisches oder nichtionisches polymer und mindestens ein carboxysilikon enthält.
PT615751E (pt) Utilizacao de antagonistas de taquinina no tratamento da emese
DE69839566D1 (de) Chimäre polypeptide, die das fragment b des shigatoxins sowie peptide von therapeutischem interesse enthalten
DE60034879T8 (de) Lantibiotikum
ES2187748T3 (es) Tejido tratado con celulasa y oxidorreductasa.
ATE334208T1 (de) Menschliche proteasen und für diese kodierende polynukleotide
AU2003304411A8 (en) Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
AR020141A1 (es) Toxinas y genes pesticidas de cepas de bacillus laterosporus
EP1191096A4 (de) Neues protein und dessen dns
DE602005010676D1 (de) Behandlung von druckgeschwüren